Review
. 2020 Jun;47(4).
doi: 10.1053/j.seminoncol.2020.05.010.

Management of hormone receptor-positive, HER2-negative early breast cancer

Elaine M Walsh 1 Karen L Smith 1 Vered Stearns 2 
Affiliations
  • PMID: 32546323
  •     123 References

Abstract

The majority of breast cancers are diagnosed at an early stage and are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative. Significant advances have been made in the management of early stage HR-positive, HER2-negative breast cancer, resulting in improved survival outcomes. In this review, we discuss important factors to consider in the management of this disease. In particular, we discuss the role of adjuvant endocrine therapy, specific endocrine therapy agents, the duration of adjuvant endocrine therapy, treatment-related side effects, and the role of genomic assays and other biomarkers when considering treatment recommendations for individuals with HR-positive, HER2-negative early breast cancer. Finally, we address emerging data to individualize therapeutic decision-making and provide future considerations.

Keywords: Breast cancer; Endocrine therapy; Hormone receptor.

Strategies for developing Ki67 as a useful biomarker in breast cancer.
Carsten Denkert, Jan Budczies, +3 authors, Frederick Klauschen.
Breast, 2015 Aug 19; 24 Suppl 2. PMID: 26283598
Review.
Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
LHRH-agonists in Early Breast Cancer Overview group, J Cuzick, +5 authors, R Sainsbury.
Lancet, 2007 May 22; 369(9574). PMID: 17512856
LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Shom Goel, Rohini Sharma, Anne Hamilton, Jane Beith.
Cochrane Database Syst Rev, 2009 Oct 13; (4). PMID: 19821328    Free PMC article.
Systematic Review.
Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration.
Samuel C Y Leung, Torsten O Nielsen, +31 authors, Mitch Dowsett.
NPJ Breast Cancer, 2016 May 18; 2. PMID: 28721378    Free PMC article.
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.
Harold J Burstein, Christina Lacchetti, +9 authors, Jennifer J Griggs.
J Clin Oncol, 2016 Feb 18; 34(14). PMID: 26884586
Highly Cited. Systematic Review.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study.
Zhao Chen, Michael Maricic, +6 authors, Meryl S Leboff.
Arch Intern Med, 2005 Mar 16; 165(5). PMID: 15767532
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.
Sukhbinder Dhesy-Thind, Glenn G Fletcher, +9 authors, Catherine H Van Poznak.
J Clin Oncol, 2017 Jun 16; 35(18). PMID: 28618241
Highly Cited. Systematic Review.
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
R C Coombes, L S Kilburn, +32 authors, Intergroup Exemestane Study.
Lancet, 2007 Feb 20; 369(9561). PMID: 17307102
Highly Cited.
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
Erik J Blok, Judith R Kroep, +10 authors, IDEAL Study Group.
J Natl Cancer Inst, 2017 Sep 20; 110(1). PMID: 28922787
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
Fabrice André, Eva Ciruelos, +18 authors, SOLAR-1 Study Group.
N Engl J Med, 2019 May 16; 380(20). PMID: 31091374
Highly Cited.
NCCN Guidelines Insights: Breast Cancer, Version 3.2018.
Matthew P Goetz, William J Gradishar, +30 authors, Rashmi Kumar.
J Natl Compr Canc Netw, 2019 Feb 23; 17(2). PMID: 30787125
Highly Cited.
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
I Craig Henderson, Donald A Berry, +16 authors, Larry Norton.
J Clin Oncol, 2003 Mar 15; 21(6). PMID: 12637460
Highly Cited.
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.
Poornima Saha, Meredith M Regan, +25 authors, International Breast Cancer Study Group.
J Clin Oncol, 2017 Jun 28; 35(27). PMID: 28654365    Free PMC article.
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
Mitch Dowsett, Ivana Sestak, +5 authors, Jack Cuzick.
J Clin Oncol, 2018 Apr 21; 36(19). PMID: 29676944    Free PMC article.
Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer.
Matteo Lambertini, Eva Blondeaux, Francesco Perrone, Lucia Del Mastro.
J Clin Oncol, 2019 Oct 17; 38(12). PMID: 31618128
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Vivianne C G Tjan-Heijnen, Irene E G van Hellemond, +14 authors, Dutch Breast Cancer Research Group (BOOG) for the DATA Investigators.
Lancet Oncol, 2017 Oct 17; 18(11). PMID: 29031778
Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
Virginia A Moyer, U.S. Preventive Services Task Force.
Ann Intern Med, 2013 Dec 25; 160(4). PMID: 24366376
Highly Cited.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
Eleftherios P Mamounas, Jong-Hyeon Jeong, +17 authors, Norman Wolmark.
J Clin Oncol, 2008 Mar 12; 26(12). PMID: 18332472
Adjuvant ovarian suppression in premenopausal breast cancer.
Prudence A Francis, Meredith M Regan, +28 authors, International Breast Cancer Study Group.
N Engl J Med, 2014 Dec 17; 372(5). PMID: 25495490    Free PMC article.
Highly Cited.
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.
Carolyn D Runowicz, Corinne R Leach, +13 authors, Patricia A Ganz.
J Clin Oncol, 2015 Dec 09; 34(6). PMID: 26644543
Highly Cited. Systematic Review.
A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors.
Jyothi S Prabhu, Aruna Korlimarla, +12 authors, T S Sridhar.
J Cancer, 2014 Feb 25; 5(2). PMID: 24563670    Free PMC article.
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.
Mitch Dowsett, Jack Cuzick, +16 authors, Richard Peto.
J Clin Oncol, 2009 Dec 02; 28(3). PMID: 19949017
Highly Cited.
Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.
Matteo Lambertini, Niels Kroman, +11 authors, Hatem A Azim.
J Natl Cancer Inst, 2017 Nov 01; 110(4). PMID: 29087485    Free PMC article.
Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.
Stephen E Jones, James Cantrell, +17 authors, Lina Asmar.
J Clin Oncol, 2007 Oct 20; 25(30). PMID: 17947724
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
Kimberly H Allison, M Elizabeth H Hammond, +17 authors, Antonio C Wolff.
J Clin Oncol, 2020 Jan 14; 38(12). PMID: 31928404
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C Wolff, M Elizabeth H Hammond, +19 authors, College of American Pathologists.
J Clin Oncol, 2013 Oct 09; 31(31). PMID: 24101045
Highly Cited.
Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors.
N Lynn Henry, Jon T Giles, +13 authors, Daniel J Clauw.
Breast Cancer Res Treat, 2007 Oct 09; 111(2). PMID: 17922185    Free PMC article.
Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it.
F Boccardo, A Rubagotti, +10 authors, A Farris.
J Clin Oncol, 2000 Jul 15; 18(14). PMID: 10894871
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M Elizabeth H Hammond, Daniel F Hayes, +29 authors, Antonio C Wolff.
Arch Pathol Lab Med, 2010 Jun 09; 134(6). PMID: 20524868    Free PMC article.
Highly Cited.
Breast cancer in men in the United States: a population-based study of diagnosis, treatment, and survival.
Linda C Harlan, Jo Anne Zujewski, Marc T Goodman, Jennifer L Stevens.
Cancer, 2010 Jun 22; 116(15). PMID: 20564105    Free PMC article.
Risk of menopause during the first year after breast cancer diagnosis.
P J Goodwin, M Ennis, +2 authors, N Hood.
J Clin Oncol, 1999 Nov 24; 17(8). PMID: 10561298
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Dejan Juric, Filip Janku, +14 authors, Hope S Rugo.
JAMA Oncol, 2018 Dec 14; 5(2). PMID: 30543347    Free PMC article.
Highly Cited.
Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA.
Daniel A Haber, Victor E Velculescu.
Cancer Discov, 2014 May 08; 4(6). PMID: 24801577    Free PMC article.
Highly Cited. Review.
Long-Term Follow-Up of the Intergroup Exemestane Study.
James P Morden, Isabel Alvarez, +18 authors, R Charles Coombes.
J Clin Oncol, 2017 May 04; 35(22). PMID: 28467729    Free PMC article.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2015 Jul 28; 386(10001). PMID: 26211827
Highly Cited.
Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.
Elisabeth Trapp, Wolfgang Janni, +18 authors, SUCCESS Study Group.
J Natl Cancer Inst, 2018 Oct 13; 111(4). PMID: 30312434
Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.
Huan Jin, Dongsheng Tu, +2 authors, Paul E Goss.
J Clin Oncol, 2011 Nov 02; 30(7). PMID: 22042967    Free PMC article.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
Jack Cuzick, Mitch Dowsett, +10 authors, John F Forbes.
J Clin Oncol, 2011 Oct 13; 29(32). PMID: 21990413
Highly Cited.
Improved web-based calculators for predicting breast carcinoma outcomes.
James S Michaelson, L Leon Chen, +3 authors, Jerry Younger.
Breast Cancer Res Treat, 2011 Feb 18; 128(3). PMID: 21327471
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.
N Lynn Henry, Mark R Somerfield, +10 authors, Vered Stearns.
J Clin Oncol, 2019 Jun 18; 37(22). PMID: 31206315
Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review.
Anthony Matthews, Susannah Stanway, +5 authors, Krishnan Bhaskaran.
BMJ, 2018 Oct 10; 363. PMID: 30297439    Free PMC article.
Systematic Review.
Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.
Siddhartha Yadav, Chunling Hu, +24 authors, Fergus J Couch.
J Clin Oncol, 2020 Mar 04; 38(13). PMID: 32125938    Free PMC article.
CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions.
Laura M Spring, Seth A Wander, Mark Zangardi, Aditya Bardia.
Curr Oncol Rep, 2019 Feb 27; 21(3). PMID: 30806829    Free PMC article.
Review.
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Fatima Cardoso, Laura J van't Veer, +32 authors, MINDACT Investigators.
N Engl J Med, 2016 Aug 25; 375(8). PMID: 27557300
Highly Cited.
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
Eleftherios P Mamounas, Hanna Bandos, +17 authors, Norman Wolmark.
Lancet Oncol, 2018 Dec 05; 20(1). PMID: 30509771    Free PMC article.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Olivia Pagani, Meredith M Regan, +32 authors, International Breast Cancer Study Group.
N Engl J Med, 2014 Jun 03; 371(2). PMID: 24881463    Free PMC article.
Highly Cited.
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
Paul E Goss, James N Ingle, +18 authors, Lois E Shepherd.
J Clin Oncol, 2013 Jan 30; 31(11). PMID: 23358971    Free PMC article.
Highly Cited.
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.
H J Burstein, G Curigliano, +11 authors, Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019.
Ann Oncol, 2019 Aug 03; 30(10). PMID: 31373601
Highly Cited.
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Paul E Goss, James N Ingle, +15 authors, Joseph L Pater.
N Engl J Med, 2003 Oct 11; 349(19). PMID: 14551341
Highly Cited.
Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Joseph Sparano, Anne O'Neill, +5 authors, Kathy D Miller.
JAMA Oncol, 2018 Jul 29; 4(12). PMID: 30054636    Free PMC article.
Highly Cited.
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Gong Tang, Steven Shak, +6 authors, Norman Wolmark.
Breast Cancer Res Treat, 2011 Jan 12; 127(1). PMID: 21221771    Free PMC article.
Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.
P M Ravdin, L A Siminoff, +4 authors, H L Parker.
J Clin Oncol, 2001 Feb 22; 19(4). PMID: 11181660
Highly Cited.
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
Joseph A Sparano, Robert J Gray, +26 authors, George W Sledge.
JAMA Oncol, 2019 Oct 01; 6(3). PMID: 31566680    Free PMC article.
A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.
Li Sun, Adam Brentnall, +15 authors, Ranjit Manchanda.
JAMA Oncol, 2019 Oct 04;. PMID: 31580391    Free PMC article.
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
BIG 1-98 Collaborative Group, Henning Mouridsen, +10 authors, Alan S Coates.
N Engl J Med, 2009 Aug 21; 361(8). PMID: 19692688    Free PMC article.
Highly Cited.
Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen.
Kathryn J Ruddy, Stephen D DeSantis, +5 authors, Ann H Partridge.
Clin Breast Cancer, 2014 Jun 28; 14(6). PMID: 24970714
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29860917    Free PMC article.
Highly Cited.
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
Harold J Burstein, Christina Lacchetti, +9 authors, Jennifer J Griggs.
J Clin Oncol, 2018 Nov 20; 37(5). PMID: 30452337
Highly Cited. Systematic Review.
Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).
Kathy D Miller, Anne O'Neill, +12 authors, George W Sledge.
J Clin Oncol, 2018 Jul 25; 36(25). PMID: 30040523    Free PMC article.
Optimal systemic therapy for early breast cancer in women: a clinical practice guideline.
A Eisen, G G Fletcher, +5 authors, members of the Early Breast Cancer Systemic Therapy Consensus Panel.
Curr Oncol, 2015 Apr 08; 22(Suppl 1). PMID: 25848340    Free PMC article.
Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline.
Charles L Shapiro, Catherine Van Poznak, +11 authors, Joan Neuner.
J Clin Oncol, 2019 Sep 19; 37(31). PMID: 31532726
Systematic Review.
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
Hongchao Pan, Richard Gray, +9 authors, EBCTCG.
N Engl J Med, 2017 Nov 09; 377(19). PMID: 29117498    Free PMC article.
Highly Cited.
Adherence to tamoxifen over the five-year course.
Timothy L Lash, Matthew P Fox, +2 authors, Rebecca A Silliman.
Breast Cancer Res Treat, 2006 Mar 17; 99(2). PMID: 16541307
Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer.
Katherine D Crew, Heather Greenlee, +5 authors, Dawn L Hershman.
J Clin Oncol, 2007 Sep 01; 25(25). PMID: 17761973
Highly Cited.
Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients.
Cary A Presant, Linda Bosserman, +6 authors, Frank Howard.
Clin Breast Cancer, 2007 Nov 21; 7(10). PMID: 18021478
Adjuvant systemic therapy for male breast carcinoma.
Sharon H Giordano, George H Perkins, +4 authors, Gabriel N Hortobagyi.
Cancer, 2005 Nov 05; 104(11). PMID: 16270318
Are SOFT and TEXT results practice changing and how?
Olivia Pagani, Meredith M Regan, Prudence A Francis.
Breast, 2016 Apr 24; 27. PMID: 27107153
Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update.
Kutluk Oktay, Brittany E Harvey, +6 authors, Alison W Loren.
J Clin Oncol, 2018 Apr 06; 36(19). PMID: 29620997
Highly Cited. Systematic Review.
An international study to increase concordance in Ki67 scoring.
Mei-Yin C Polley, Samuel C Y Leung, +28 authors, Torsten O Nielsen.
Mod Pathol, 2015 Feb 24; 28(6). PMID: 25698062
Highly Cited.
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
Joanne L Blum, Patrick J Flynn, +19 authors, Norman Wolmark.
J Clin Oncol, 2017 Apr 12; 35(23). PMID: 28398846    Free PMC article.
Highly Cited.
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Michael Gnant, Brigitte Mlineritsch, +18 authors, Austrian Breast and Colorectal Cancer Study Group (ABCSG).
Lancet Oncol, 2008 Aug 23; 9(9). PMID: 18718815
Preoperative chemotherapy for women with operable breast cancer.
J S D Mieog, J A van der Hage, C J H van de Velde.
Cochrane Database Syst Rev, 2007 Apr 20; (2). PMID: 17443564    Free PMC article.
Systematic Review.
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Lyndsay N Harris, Nofisat Ismaila, +11 authors, American Society of Clinical Oncology.
J Clin Oncol, 2016 Feb 10; 34(10). PMID: 26858339    Free PMC article.
Highly Cited. Review.
Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer.
Erin J Aiello Bowles, Denise M Boudreau, +4 authors, Diana S M Buist.
J Oncol Pract, 2013 Apr 20; 8(6). PMID: 23598850    Free PMC article.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Christina Davies, Hongchao Pan, +36 authors, Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.
Lancet, 2012 Dec 12; 381(9869). PMID: 23219286    Free PMC article.
Highly Cited.
An international Ki67 reproducibility study.
Mei-Yin C Polley, Samuel C Y Leung, +16 authors, International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group.
J Natl Cancer Inst, 2013 Nov 10; 105(24). PMID: 24203987    Free PMC article.
Highly Cited.
Direct detection of early-stage cancers using circulating tumor DNA.
Jillian Phallen, Mark Sausen, +34 authors, Victor E Velculescu.
Sci Transl Med, 2017 Aug 18; 9(403). PMID: 28814544    Free PMC article.
Highly Cited.
Understanding the utility of adjuvant systemic therapy for primary breast cancer.
C L Loprinzi, S D Thomé.
J Clin Oncol, 2001 Feb 22; 19(4). PMID: 11181659
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
Paul E Goss, James N Ingle, +17 authors, Wendy R Parulekar.
N Engl J Med, 2016 Jun 07; 375(3). PMID: 27264120    Free PMC article.
Highly Cited.
Germline Genetic Testing for Breast Cancer Risk: The Past, Present, and Future.
Siddhartha Yadav, Fergus J Couch.
Am Soc Clin Oncol Educ Book, 2019 May 18; 39. PMID: 31099663
Review.
CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer?
Mirat Shah, Maria Raquel Nunes, Vered Stearns.
Oncology (Williston Park), 2018 May 31; 32(5). PMID: 29847850    Free PMC article.
Review.
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.
Peyman Hadji, Matti S Aapro, +18 authors, Robert E Coleman.
J Bone Oncol, 2017 Apr 18; 7. PMID: 28413771    Free PMC article.
Highly Cited. Review.
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.
Robert Coleman, Dianne M Finkelstein, +14 authors, Arlene Chan.
Lancet Oncol, 2019 Dec 07; 21(1). PMID: 31806543
Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer.
C L Shapiro, J Manola, M Leboff.
J Clin Oncol, 2001 Jul 17; 19(14). PMID: 11454877
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Paul E Goss, James N Ingle, +15 authors, Joseph L Pater.
J Natl Cancer Inst, 2005 Sep 08; 97(17). PMID: 16145047
Highly Cited.
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Michael Gnant, Georg Pfeiler, +17 authors, Austrian Breast and Colorectal Cancer Study Group.
Lancet Oncol, 2019 Feb 24; 20(3). PMID: 30795951
Highly Cited.
Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
Andrew G Glass, James V Lacey, J Daniel Carreon, Robert N Hoover.
J Natl Cancer Inst, 2007 Jul 27; 99(15). PMID: 17652280
Highly Cited.
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
A Howell, J Cuzick, +8 authors, ATAC Trialists' Group.
Lancet, 2005 Jan 11; 365(9453). PMID: 15639680
Highly Cited.
NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.
D Craig Allred, Robert W Carlson, +11 authors, Antonio C Wolff.
J Natl Compr Canc Netw, 2009 Dec 03; 7 Suppl 6. PMID: 19755043
Review.
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
Dennis J Slamon, Patrick Neven, +18 authors, Guy Jerusalem.
N Engl J Med, 2019 Dec 12; 382(6). PMID: 31826360
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.
Harold J Burstein, Ann Alexis Prestrud, +16 authors, American Society of Clinical Oncology.
J Clin Oncol, 2010 Jul 14; 28(23). PMID: 20625130    Free PMC article.
Highly Cited. Systematic Review.
Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer.
Jason R Brown, Michael P DiGiovanna, +2 authors, David L Rimm.
Lab Invest, 2013 Nov 06; 94(1). PMID: 24189270
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2019 Jun 04; 380(25). PMID: 31157962    Free PMC article.
Highly Cited.
Adjuvant endocrine therapy for premenopausal women with breast cancer.
Shannon Puhalla, Adam Brufsky, Nancy Davidson.
Breast, 2009 Nov 17; 18 Suppl 3. PMID: 19914530    Free PMC article.
Review.
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
Eleftherios P Mamounas, John Bryant, +7 authors, Norman Wolmark.
J Clin Oncol, 2005 May 18; 23(16). PMID: 15897552
Highly Cited.
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2015 Jul 28; 386(10001). PMID: 26211824
Highly Cited.
Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women.
S Demissie, R A Silliman, T L Lash.
J Clin Oncol, 2001 Feb 24; 19(2). PMID: 11208822
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations.
N Lynn Henry, Mark R Somerfield, +6 authors, Ian E Krop.
J Clin Oncol, 2016 Mar 24; 34(19). PMID: 27001586
Breast Cancer in Men.
Sharon H Giordano.
N Engl J Med, 2018 Oct 04; 379(14). PMID: 30281998
PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2.
G C Wishart, C D Bajdik, +34 authors, P D P Pharoah.
Br J Cancer, 2012 Aug 02; 107(5). PMID: 22850554    Free PMC article.
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
Ulrike Nitz, Oleg Gluz, +18 authors, West German Study Group PlanB Investigators.
J Clin Oncol, 2019 Feb 21; 37(10). PMID: 30785826
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
George W Sledge, Masakazu Toi, +16 authors, Antonio Llombart-Cussac.
JAMA Oncol, 2019 Sep 30;. PMID: 31563959    Free PMC article.
Highly Cited.
Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.
Salomon M Stemmer, Mariana Steiner, +13 authors, Noa Ben-Baruch.
NPJ Breast Cancer, 2017 Sep 14; 3. PMID: 28900632    Free PMC article.
NCCN Task Force Report: Bone Health In Cancer Care.
Julie R Gralow, J Sybil Biermann, +8 authors, Catherine H Van Poznak.
J Natl Compr Canc Netw, 2013 Sep 06; 11 Suppl 3. PMID: 23997241
Review.
Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis.
Hadar Goldvaser, Tristan A Barnes, +4 authors, Eitan Amir.
J Natl Cancer Inst, 2017 Sep 20; 110(1). PMID: 28922781
Review.
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions.
Ryan J O Dowling, Joseph A Sparano, +29 authors, Daniel F Hayes.
JNCI Cancer Spectr, 2020 Apr 28; 3(4). PMID: 32337478    Free PMC article.
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.
C L Shapiro, S Halabi, +10 authors, E Paskett.
Eur J Cancer, 2011 Feb 18; 47(5). PMID: 21324674    Free PMC article.
Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.
Lesley J Fallowfield, Judith M Bliss, +5 authors, Emma Hall.
J Clin Oncol, 2006 Feb 18; 24(6). PMID: 16484701
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), C Davies, +11 authors, R Peto.
Lancet, 2011 Aug 02; 378(9793). PMID: 21802721    Free PMC article.
Highly Cited.
Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.
Laura M Spring, Arjun Gupta, +5 authors, Aditya Bardia.
JAMA Oncol, 2016 Jul 02; 2(11). PMID: 27367583    Free PMC article.
Highly Cited. Systematic Review.
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M Elizabeth H Hammond, Daniel F Hayes, +29 authors, Antonio C Wolff.
J Clin Oncol, 2010 Apr 21; 28(16). PMID: 20404251    Free PMC article.
Highly Cited. Systematic Review.
Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy.
Yan Jin, Daniel F Hayes, +10 authors, Vered Stearns.
J Clin Oncol, 2008 Nov 20; 26(36). PMID: 19018086    Free PMC article.
Molecular Characterization and Mortality From Breast Cancer in Men.
Suleiman Alfred Massarweh, George W Sledge, +3 authors, Steven Shak.
J Clin Oncol, 2018 Mar 28; 36(14). PMID: 29584547    Free PMC article.
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Marco Colleoni, Weixiu Luo, +30 authors, SOLE Investigators.
Lancet Oncol, 2017 Nov 22; 19(1). PMID: 29158011
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.
Cornelis J H van de Velde, Daniel Rea, +14 authors, Stephen E Jones.
Lancet, 2011 Jan 21; 377(9762). PMID: 21247627
Highly Cited.
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Prudence A Francis, Olivia Pagani, +34 authors, SOFT and TEXT Investigators and the International Breast Cancer Study Group.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29863451    Free PMC article.
Highly Cited.
The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies.
Peyman Hadji, Lina Asmar, +7 authors, May Ziller.
J Cancer Res Clin Oncol, 2010 Dec 21; 137(6). PMID: 21170551
Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.
Meredith M Regan, Olivia Pagani, +12 authors, GroupSOFT and TEXT Investigators.
Breast, 2013 Oct 08; 22(6). PMID: 24095609    Free PMC article.